 |
SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has commenced its second registrational Phase III 64Cu-SAR-bis...
As residential developers continue to grapple with feasibility issues on apartment projects, the sector is struggling to deliver volumes of new st...
Rising dissatisfaction with pay, progression and perks is fuelling a new wave of career change in FY25/26, as Australians demand more from employe...
Data Governance Failures, ROI Gaps and Unclear Strategy Slowing Progress Despite artificial intelligence (AI) dominating headlines and boardroom ag...
Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...
AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...
For many Australian businesses, growth increasingly depends on thinking beyond local borders. As wage pressures rise, and specialised talent pool...
